Tech Center 1600 • Art Units: 1623 1673 1693
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18027763 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING AUTOIMMUNE DISORDERS | Final Rejection | The Regents of the University of Michigan |
| 18569169 | A NON-THERAPEUTIC COSMETIC METHOD FOR REDUCING WRINKLES ON A SKIN SURFACE | Non-Final OA | L'Oreal |
| 18252077 | NUTRITIONAL COMPOSITION | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18251950 | SELF-REPAIRING BIOMIMETIC LUBRICANTS AND METHODS OF MAKING AND USING SAME | Non-Final OA | Duke University |
| 18555582 | FUCOSYLATION AND IMMUNE MODULATION IN CANCER | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18549797 | NOVEL DEALKOXYPHENYLATION REACTION | Non-Final OA | Daiichi Sankyo Company, Limited |
| 18550349 | GLYCOSIDE INHIBITORS OF YEAST | Non-Final OA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS |
| 18034651 | IMMUNOMODULATORY AGENT | Non-Final OA | THE QUEEN'S UNIVERSITY OF BELFAST |
| 18564361 | NOVEL COMPOUND ISOLATED FROM SPINACH, AND COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING INFLAMMATORY DISEASES | Non-Final OA | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 18464082 | ORAL CANINE FEED AND METHODS FOR CONTROLLING FLEA INFESTATIONS IN A CANINE | Non-Final OA | In the Bowl Animal Health, Inc. |
| 17593529 | COMPOSITIONS COMPRISING POLAR LIPIDS FOR MAINTAINING OR INCREASING MOBILITY AND VITALITY | Non-Final OA | FONTERRA CO-OPERATIVE GROUP LIMITED |
| 18564611 | AN IMPROVED PROCESS FOR THE PREPARATION OF (4R)-1-[(2R,4R,5R)-3,3-DIFLUORO-4-HYDROXY-5-(HYDROXYMETHYL) OXOLAN-2-YL]-4-HYDROXY-1,3-DIAZINAN-2ONE AND ITS INTERMEDIATE COMPOUNDS | Non-Final OA | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER |
| 18253155 | Agent for Adjusting Hardness of Lens of Eye | Final Rejection | Tsubota Laboratory, Inc. |
| 18501539 | TUMESCENT SOLUTION WITH B VITAMINS | Non-Final OA | HK Pharma |
| 18262174 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | Non-Final OA | Augusta University Research Institute, Inc. |
| 18200747 | METHODS FOR IMPROVING MUSCLE STRENGTH AND MOBILITY | Non-Final OA | Intrinsic Medicine, Inc. |
| 18286416 | NUCLEOSIDE ANALOG AND USE THEREOF | Non-Final OA | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES |
| 18553882 | A COMPOSITION FOR PROMOTING GLP-1 SECRETION | Non-Final OA | Hayashibara Co., Ltd. |
| 18023325 | METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE WITH CYCLODEXTRINS | Final Rejection | Beren Therapeutics P.B.C. |
| 18043009 | METHODS FOR THE PREVENTION OF CHOLESTEROL CRYSTAL EMBOLIZATION WITH CYCLODEXTRINS | Final Rejection | Beren Therapeutics P.B.C. |
| 18043013 | METHODS FOR THE TREATMENT OF CHOLESTEROL CRYSTAL EMBOLIZATION WITH CYCLODEXTRINS | Non-Final OA | Beren Therapeutics P.B.C. |
| 18271296 | Use of Inosine in Preparing Drug For Treatment of Corona Virus Disease 2019 | Non-Final OA | PLA ACADEMY OF MILITARY MEDICAL SCIENCES |
| 18270214 | ANTI-OBESITY COMPOSITION CONTAINING, AS ACTIVE INGREDIENT, MORINGA OLEIFERA FERMENTATION PRODUCT PREPARED USING NOVEL MONASCUS PURPUREUS SL1 | Non-Final OA | MBIOMETHERAPEUTICS CO., LTD. |
| 18269748 | Composition for Oral Cavity | Non-Final OA | SUNSTAR SUISSE SA |
| 18031670 | COMPOSITION FOR PREVENTION, AMELIORATION, OR TREATMENT OF HYPERSENSITIVITY IMMUNE DISEASE CONTAINING GALACTOSE | Final Rejection | Quorum Bio Co., Ltd. |
| 18030947 | METHOD OF SELECTING COMPOSITIONS COMPRISING CROSSLINKED HYALURONIC ACID AND A LOW PROPORTION OF SOLUBLE HYALURONIC ACID OF LOW MOLECULAR WEIGHT | Final Rejection | TEOXANE SA |
| 17794577 | LOCALIZED EXPRESSION OF THERAPEUTIC NUCLEIC ACIDS IN LUNG EPITHELIAL CELLS | Non-Final OA | ENGENE, INC. |
| 18120659 | COMPOSITIONS FOR IMPROVING JOINT HEALTH | Final Rejection | BioRelief, LLC |
| 17620465 | ISOLATION OF NUCLEIC ACIDS AT ELEVATED TEMPERATURES | Final Rejection | Bioecho Life Sciences GMBH |
| 17920266 | BIOCOMPATIBLE MATERIAL AND METHODS FOR MAKING AND USING THE SAME | Final Rejection | PLERYON THERAPEUTICS (SHENZHEN) LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy